Aspen Drug Patent Portfolio
Aspen owns 2 orange book drugs protected by 3 US patents Given below is the list of Aspen's drug patents along with their expiration dates.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US6660726 | Estrogenic compounds, pharmaceutical compositions thereof, and methods of using same | 08 Mar, 2021 | Expired |
| US6855703 | Pharmaceutical compositions of conjugated estrogens and methods of analyzing mixtures containing estrogenic compounds | 12 Feb, 2021 | Expired |
| US5908638 | Pharmaceutical compositions of conjugated estrogens and methods for their use | 26 Jul, 2015 | Expired |
Latest Legal Activities on Aspen's Drug Patents
Given below is the list of recent legal activities going on the following drug patents of Aspen.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Post Issue Communication - Certificate of Correction | 12 May, 2004 | US6660726 |
|
Patent Issue Date Used in PTA Calculation
Critical
| 09 Dec, 2003 | US6660726 |
|
Recordation of Patent Grant Mailed
Critical
| 09 Dec, 2003 | US6660726 |
|
Issue Notification Mailed
Critical
| 20 Nov, 2003 | US6660726 |
| Receipt into Pubs | 27 Oct, 2003 | US6660726 |
|
Mail Response to 312 Amendment (PTO-271)
Critical
| 23 Oct, 2003 | US6660726 |
|
Response to Amendment under Rule 312
Critical
| 23 Oct, 2003 | US6660726 |
|
Application Is Considered Ready for Issue
Critical
| 23 Oct, 2003 | US6660726 |
| Receipt into Pubs | 20 Oct, 2003 | US6660726 |
| Workflow - File Sent to Contractor | 25 Aug, 2003 | US6660726 |
| Receipt into Pubs | 25 Aug, 2003 | US6660726 |
| Dispatch to Publications | 22 Aug, 2003 | US6660726 |
|
Issue Fee Payment Received
Critical
| 16 Jun, 2003 | US6660726 |
|
Amendment after Notice of Allowance (Rule 312)
Critical
| 16 Jun, 2003 | US6660726 |
|
Issue Fee Payment Verified
Critical
| 16 Jun, 2003 | US6660726 |
Aspen's Drug Patent Litigations
Aspen's drugs have been subject to various legal proceedings, including patent litigations. The earliest legal proceeding was initiated on Mar 12, 2003, against patent number US6855703. The petitioner , challenged the validity of this patent, with Edward N Hill et al as the respondent. Click below to track the latest information on how companies are challenging Aspen's patents.
| Patent | Proceeding Filing Date | Status | Respondent | Petitioner |
|---|---|---|---|---|
 | ||||
| US6855703 | March, 2003 |
Decision
(11 Feb, 2004)
| Edward N Hill et al | |
Aspen's Family Patents
Aspen Drug List
Given below is the complete list of Aspen's drugs and the patents protecting them.
1. Cenestin
Cenestin is protected by 1 patent, which has expired already. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US5908638 | Pharmaceutical compositions of conjugated estrogens and methods for their use |
26 Jul, 2015
(9 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Cenestin's drug page
2. Enjuvia
Enjuvia is protected by 2 patents, out of which all have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US6660726 | Estrogenic compounds, pharmaceutical compositions thereof, and methods of using same |
08 Mar, 2021
(3 years ago)
| Expired |
| US6855703 | Pharmaceutical compositions of conjugated estrogens and methods of analyzing mixtures containing estrogenic compounds |
12 Feb, 2021
(3 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Enjuvia's drug page